The best weight loss treatment for women in the UK depends on your starting weight, underlying conditions such as PCOS or menopause, and whether you qualify for NHS prescriptions. In 2027, the most effective options are tirzepatide (Mounjaro) and semaglutide (Wegovy), both of which produce greater weight loss in women than in men according to clinical trial subgroup analyses. For women with a BMI of 30 or above (or 27 with a weight-related condition), these prescription medications can be obtained through NHS specialist weight management services or private clinics. Over-the-counter orlistat (Alli) is available from pharmacies without a prescription for women with a BMI of 28 or above.
This guide covers every evidence-based weight loss option available to women in the UK, from NHS referral pathways to private prescriptions, with specific sections on menopause-related weight gain and PCOS.
Why is weight loss harder for women?
Women face biological challenges that make losing weight more difficult than it is for men. Understanding these differences helps explain why a one-size-fits-all approach rarely works.
Lower basal metabolic rate. Women naturally have a higher proportion of body fat and less lean muscle mass than men. Since muscle burns more calories at rest, women's metabolic rate is typically 5 to 10 per cent lower, meaning they burn fewer calories doing nothing.
Hormonal fluctuations. Oestrogen, progesterone and testosterone levels shift throughout the menstrual cycle, during pregnancy, postpartum and through perimenopause. These fluctuations affect appetite, fat storage patterns and water retention. Many women notice their weight can vary by 1 to 3 kg across a single cycle.
Fat distribution. Before menopause, oestrogen directs fat storage to the hips and thighs (a pattern linked to lower cardiovascular risk). After menopause, declining oestrogen causes a shift toward abdominal fat storage, which is associated with higher risks of type 2 diabetes and heart disease.
PCOS and insulin resistance. Polycystic ovary syndrome affects roughly 1 in 10 women in the UK. It causes insulin resistance, which makes the body store fat more readily and makes weight loss significantly harder without targeted treatment.
Menopause and weight gain: what the evidence shows
Most women gain between 2 and 5 kg during the menopausal transition, typically between ages 45 and 55. This is not simply a matter of eating more. The drop in oestrogen triggers several metabolic changes at once.
| Change | What happens | Effect on weight |
|---|---|---|
| Oestrogen decline | Fat shifts from hips and thighs to the abdomen | Increased visceral fat, higher cardiovascular risk |
| Muscle mass loss | Sarcopenia accelerates after 50, reducing metabolic rate | Fewer calories burned at rest (roughly 100 kcal/day less) |
| Sleep disruption | Hot flushes and night sweats disturb sleep quality | Poor sleep raises ghrelin (hunger hormone) and lowers leptin (satiety) |
| Insulin sensitivity | Cells become less responsive to insulin | Blood sugar spikes, increased fat storage, cravings |
| Thyroid function | Hypothyroidism risk increases after 50 | Slowed metabolism, fatigue, weight gain |
Does HRT help with weight? Hormone replacement therapy does not directly cause weight loss, but several studies show it can prevent the shift to abdominal fat storage. Women on HRT tend to maintain a healthier fat distribution pattern. If you are considering HRT for menopausal symptoms, discuss the potential weight-related benefits with your GP.
PCOS and weight management
Polycystic ovary syndrome affects approximately 1 in 10 women of reproductive age in the UK. Weight management is a cornerstone of PCOS treatment because even a 5 to 10 per cent reduction in body weight can restore ovulation, improve insulin sensitivity, reduce testosterone levels and lower the risk of type 2 diabetes.
Why PCOS makes weight loss harder. Insulin resistance is present in up to 70 per cent of women with PCOS, regardless of their weight. The body produces more insulin to compensate, which promotes fat storage and makes it harder to burn stored fat. Many women with PCOS also have higher levels of androgens (male hormones), which can increase appetite and alter where fat is stored.
NICE-recommended treatments for PCOS and weight. The NICE guideline on PCOS (NG217) recommends lifestyle modification as first-line treatment. Metformin may be considered for metabolic features where lifestyle changes have not been effective, particularly in women with a BMI of 25 or above. GLP-1 receptor agonists such as semaglutide and tirzepatide are showing promising results for PCOS in emerging research, though they are not yet specifically licensed for PCOS in the UK. Several studies have shown GLP-1 medications improve insulin resistance, reduce androgen levels and support weight loss in women with PCOS.
What weight loss medications are available for women in the UK?
Five prescription weight loss medications are currently available in the UK, plus one over-the-counter option. All of them have been studied in women, and two of the newest options actually work better in women than men.
| Medication | Brand | How it works | Average weight loss | NHS available | Monthly cost (private) |
|---|---|---|---|---|---|
| Tirzepatide | Mounjaro | GLP-1 + GIP dual agonist (weekly injection) | 15 to 22% body weight | Yes (specialist services) | £150 to £230 |
| Semaglutide 2.4 mg | Wegovy | GLP-1 receptor agonist (weekly injection) | 12 to 15% body weight | Yes (specialist services) | £150 to £200 |
| Liraglutide 3 mg | Saxenda | GLP-1 receptor agonist (daily injection) | 5 to 8% body weight | Limited | £150 to £200 |
| Orlistat 120 mg | Xenical | Fat absorption blocker (capsule with meals) | 3 to 5% body weight | Yes (GP prescription) | £18 to £30 |
| Orlistat 60 mg | Alli | Fat absorption blocker (OTC capsule) | 2 to 3% body weight | N/A (pharmacy sale) | £30 to £50 |
| Naltrexone/bupropion | Mysimba | Appetite and craving reducer (oral tablet) | 5 to 8% body weight | Limited | £70 to £100 |
How much weight do women actually lose? The clinical evidence
Both tirzepatide and semaglutide have been shown to produce greater weight loss in women than in men in large clinical trials. This is significant because most older weight loss medications showed no sex-based difference.
Tirzepatide (Mounjaro) in women. A subgroup analysis of the SURMOUNT clinical trials, published in 2025, found that women treated with tirzepatide at the highest dose (15 mg) lost an average of 24.4 per cent of their body weight, compared with 19.4 per cent for men. For a woman weighing 90 kg, that represents a loss of roughly 22 kg over 72 weeks. The researchers noted that women had a stronger response to the GIP component of the dual agonist.
Semaglutide (Wegovy) in women. Data presented at the American College of Cardiology in 2024 showed that semaglutide produced greater weight loss in women than men across the STEP-HFpEF trials. Women lost an average of 10.1 per cent of body weight compared with 5.9 per cent for men. While this particular trial involved patients with heart failure, subgroup analyses from the broader STEP programme consistently show women responding at least as well as, and often better than, men.
What this means for you. If you are a woman considering prescription weight loss medication in the UK, the evidence suggests you may see results at or above the headline trial figures. The two most effective options, tirzepatide and semaglutide, appear to work particularly well in women.
NHS weight loss pathway: how to get help
The NHS offers a structured pathway for weight management. Here is how to access it.
Step 1: See your GP. Your GP can assess your BMI, check for underlying conditions (thyroid problems, PCOS, Cushing's syndrome) and discuss your options. They can prescribe orlistat directly if your BMI is 28 or above with a weight-related condition, or 30 or above without one.
Step 2: NHS Digital Weight Management Programme. Available to adults with a BMI of 30 or above (27.5 for certain ethnic groups) who also have diabetes, high blood pressure or both. This free 12-week online programme provides coaching on diet, exercise and behaviour change. Your GP can refer you.
Step 3: Specialist weight management service. For Wegovy or Mounjaro on the NHS, you typically need a referral to a Tier 3 specialist weight management service. NICE Technology Appraisal 875 (semaglutide) and TA1026 (tirzepatide) set the criteria: BMI of 35 or above with a weight-related comorbidity, or BMI of 40 or above. The service usually requires a period of lifestyle intervention before prescribing medication.
Step 4: Bariatric surgery. For women with a BMI of 40 or above (35 with comorbidities) who have not responded to other treatments, surgical options include gastric sleeve, gastric bypass and gastric band. NHS waiting lists can be long, typically 1 to 3 years.
Private alternatives. If you do not meet NHS criteria or want faster access, private online clinics can prescribe Wegovy, Mounjaro or Saxenda after an online consultation. Expect to pay £150 to £250 per month for medication plus consultation fees. Make sure any clinic is registered with the Care Quality Commission (CQC) and that prescribers are registered with the General Medical Council (GMC) or General Pharmaceutical Council (GPhC).
Over-the-counter options: what you can buy without a prescription
The only licensed over-the-counter weight loss medication in the UK is orlistat 60 mg (Alli). It is available from pharmacies for women with a BMI of 28 or above. Alli works by blocking the absorption of roughly a quarter of the fat you eat. It is less effective than the prescription-strength 120 mg version and significantly less effective than the newer GLP-1 medications.
What about supplements? Weight loss supplements such as raspberry ketones, green tea extract, glucomannan, and apple cider vinegar capsules are widely sold in the UK but none have strong clinical evidence supporting significant weight loss. The NHS does not recommend any over-the-counter supplement for weight loss. If a product promises rapid weight loss without dietary changes, treat the claim with scepticism.
Meal replacement programmes. Structured meal replacement plans (such as those available through the NHS Diabetes Prevention Programme) can support weight loss of 5 to 10 per cent. These are most effective when used as part of a supervised programme rather than purchased independently.
What actually works alongside medication: evidence-based lifestyle changes
Medication alone produces better results than lifestyle changes alone, but the best outcomes come from combining both. These are the strategies with the strongest evidence for women specifically.
Resistance training. Preserving and building muscle mass is especially important during menopause and while using GLP-1 medications, which can cause some muscle loss alongside fat loss. Aim for two to three sessions per week. This does not mean heavy bodybuilding; bodyweight exercises, resistance bands and moderate weights all count.
Protein intake. Women over 40 benefit from higher protein intake to offset age-related muscle loss. Aim for 1.2 to 1.6 g per kg of body weight per day, spread across meals. This is particularly important when using GLP-1 medications, which reduce appetite and can make it harder to eat enough protein.
Mediterranean-style eating. The Mediterranean diet has the strongest evidence base for cardiovascular health and sustainable weight management in women. It emphasises vegetables, fruits, whole grains, legumes, fish and olive oil, with moderate dairy and limited processed food.
Sleep. Poor sleep is directly linked to weight gain, particularly in perimenopausal and menopausal women. Aim for 7 to 9 hours. If hot flushes are disrupting your sleep, discuss HRT or other management options with your GP, as improving sleep quality can itself support weight loss.
How to choose the right approach for your situation
| Your situation | Recommended first step | Best medication option |
|---|---|---|
| BMI 25 to 27, no health conditions | Lifestyle changes (diet + exercise) | None (not eligible for prescription medication) |
| BMI 28 to 29, wants pharmacy-only option | Speak to pharmacist | Alli (orlistat 60 mg, OTC) |
| BMI 30+, wants GP-prescribed option | GP appointment | Orlistat 120 mg or Mysimba (GP can prescribe) |
| BMI 30+, wants most effective option | Private clinic or NHS referral | Mounjaro or Wegovy |
| BMI 30+ with PCOS | GP for PCOS assessment + metformin | Metformin first line; GLP-1 agonist if insufficient |
| Perimenopausal or menopausal, gaining weight | GP for menopause review (HRT discussion) | HRT for symptom relief + weight medication if BMI qualifies |
| BMI 40+ or 35+ with comorbidities, tried other options | NHS Tier 3 referral | Mounjaro/Wegovy via specialist; consider bariatric surgery |
Frequently asked questions
What is the best weight loss tablet for women over 40 in the UK?
For women over 40 who meet the BMI criteria, tirzepatide (Mounjaro) currently produces the best results, with clinical trials showing women lose an average of 22 to 24 per cent of their body weight. Semaglutide (Wegovy) is the next most effective option at 12 to 15 per cent. Both are available through NHS specialist services or private clinics. If you have a BMI of 28 to 30, orlistat (available without prescription as Alli) is a more accessible starting point, though results are more modest at 2 to 5 per cent weight loss. Read our full guide to weight loss injections in the UK for a detailed comparison.
Can you get weight loss injections on the NHS?
Yes. Wegovy (semaglutide) and Mounjaro (tirzepatide) are both approved by NICE for NHS use through specialist weight management services. You will need a GP referral to a Tier 3 service, and typically need a BMI of 35 or above with a weight-related condition (or 40 or above without one). Waiting times vary by area but are often several months. See our guide on how to get Ozempic in the UK for more on the NHS pathway.
Does HRT cause weight loss during menopause?
HRT does not directly cause weight loss. However, evidence suggests that HRT can prevent the menopause-related shift of fat from the hips to the abdomen. Women using HRT tend to have less visceral (belly) fat than those who do not. HRT may also improve sleep and energy levels, which can indirectly support weight management. HRT and weight loss medications can be used at the same time if clinically appropriate.
Is metformin used for weight loss in the UK?
Metformin is not specifically licensed for weight loss in the UK. However, it is commonly prescribed for women with PCOS and insulin resistance, where it can support modest weight loss of 2 to 3 per cent alongside improvements in insulin sensitivity and menstrual regularity. Some private clinics prescribe it off-label for weight management, but GLP-1 medications are significantly more effective for weight loss alone.
How long does it take for weight loss medication to work?
Most women notice reduced appetite within the first 1 to 2 weeks of starting a GLP-1 medication. Measurable weight loss typically begins within 4 weeks, with the most significant results seen between 3 and 6 months. GLP-1 medications are titrated up gradually (starting at a lower dose and increasing every 4 weeks) to minimise side effects, so the full weight loss effect builds over time. Orlistat works from the first dose but produces slower, more modest results.
What are the side effects of weight loss medications for women?
The most common side effects of GLP-1 medications (Mounjaro, Wegovy, Saxenda) are nausea, vomiting, diarrhoea and constipation. These are usually mild and improve as your body adjusts. For women specifically, irregular periods have been reported in some cases, and women using hormonal contraception should be aware that GLP-1 medications can affect absorption of oral contraceptives during episodes of vomiting. Orlistat causes oily or fatty stools, particularly if you eat high-fat meals, and can reduce absorption of fat-soluble vitamins (A, D, E, K). A daily multivitamin is recommended while taking orlistat.
What BMI do you need for weight loss medication in the UK?
For prescription orlistat (Xenical), you need a BMI of 28 or above with a weight-related condition, or 30 or above without one. For GLP-1 medications like Wegovy and Mounjaro through NHS specialist services, the threshold is typically a BMI of 35 or above with a comorbidity, or 40 or above without one. Private clinics may prescribe at a BMI of 30 or above. The over-the-counter version of orlistat (Alli, 60 mg) is available from pharmacies for anyone with a BMI of 28 or above.
Can you take weight loss medication while breastfeeding?
No. GLP-1 medications (Mounjaro, Wegovy, Saxenda) are not recommended during breastfeeding because it is unknown whether they pass into breast milk. Orlistat is also not recommended while breastfeeding as it may reduce the absorption of fat-soluble vitamins needed by both mother and baby. If you are breastfeeding and want to lose weight, speak to your GP about safe dietary and exercise approaches. Weight loss medication can usually be considered once breastfeeding has ended.
Can you take weight loss injections with HRT?
Yes. GLP-1 medications such as Wegovy and Mounjaro can generally be taken alongside hormone replacement therapy (HRT). There is no known interaction between GLP-1 receptor agonists and oestrogen or progesterone preparations. However, if you experience vomiting as a side effect of a GLP-1 medication, this could reduce the effectiveness of oral HRT (tablets). Transdermal HRT (patches, gels or sprays) is not affected by vomiting. Always inform your prescriber about all medications you are taking.
How much does Mounjaro cost privately in the UK?
Private Mounjaro prescriptions in the UK typically cost between £150 and £230 per month depending on the dose and provider. Most private clinics charge an additional consultation fee of £20 to £50. The starting dose (2.5 mg) is usually at the lower end of the price range, with costs increasing as you titrate up to higher doses. Some clinics offer subscription models or bulk-purchase discounts. Always use a CQC-registered clinic with GMC or GPhC-registered prescribers. Compare costs from our guide on Wegovy vs Mounjaro UK.
Is it safe to take weight loss medication during perimenopause?
Yes. GLP-1 medications are considered safe for perimenopausal women who meet the BMI criteria. In fact, starting weight management during perimenopause rather than waiting until after menopause may be beneficial, as it can help prevent the shift to abdominal fat storage that occurs with declining oestrogen. There are no specific contraindications related to perimenopause. However, GLP-1 medications may affect menstrual patterns, which can make it harder to track cycle changes that are also occurring due to perimenopause. Discuss this with your prescriber so you can distinguish between medication effects and natural hormonal changes.
What is the fastest way for a woman to lose weight in the UK?
The fastest evidence-based weight loss for women comes from tirzepatide (Mounjaro), which produces average losses of 22 to 24 per cent of body weight in women over 72 weeks. This equates to roughly 0.5 to 1 kg per week on average. While crash diets may produce faster short-term results, they typically lead to muscle loss and weight regain. Sustainable, medically supervised weight loss at 0.5 to 1 kg per week is recommended by the NHS and NICE. Combining a GLP-1 medication with resistance training and adequate protein intake gives the best long-term results for women.
From the Vena Cava Blog
- Wegovy vs Mounjaro UK: Cost, Weight Loss, Side Effects Compared
- How to Get Ozempic in the UK: NHS vs Private Prescription Guide
- Mounjaro vs Ozempic UK: 5 Key Differences for Weight Loss
Medical disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any weight loss medication. Vena Cava Ltd is a medical supplies company and does not sell prescription medications. Content reviewed by a qualified healthcare professional. Last updated: October 2026.
